Can Antibodies Against Glial Derived Antigens be Early Biomarkers of Hippocampal Demyelination and Memory Loss in Alzheimer’s Disease?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Alzheimer’s disease (AD) is known to exhibit well characterized pathologies including the extracellular accumulation of amyloid plaques, intra-axonal presence of neurofibrillary tangles, and glial hypertrophy. Nevertheless, the nature of myelin pathology in AD has not been well studied. Recent studies on animal models of AD, however, revealed focal demyelination within amyloid- β plaques in hippocampus. Objectives: In a view of this finding, we decided to assess humoral response against proteins of myelin sheath in AD, in the hope of identifying early biomarkers of memory loss and neuropathological process characteristic of AD. Methods: We assessed antibodies levels against proteins of the myelin sheath: myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), myelin-associated glycoprotein (MAG), and proteolipoprotein (PLP) in sera of 26 AD patients and 26 healthy controls, using commercially available ELISA system (Mediagnost, Germany). Results: In the AD patient subgroup, significantly higher titers were observed for all types of assessed IgG autoantibodies compared to healthy control subjects (anti-MOG, anti-MAG, anti-MBP, anti-PLP). The titers of most of the investigated IgM antibodies were also higher in AD patients ( p < 0.05), with the exception of anti-MAG IgM antibodies ( p > 0.05). Conclusion: The study provides the evidence for the significantly increased production of autoantibodies against proteins of myelin sheath in AD. These results can be of importance in the light of emerging data from animal models of AD, indicating early demyelination of hippocampal region. Further studies on larger population are necessary to confirm whether these autoantibodies could serve as early biomarkers of AD in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blood–brain barrier: Ageing and microvascular disease – systematic review and meta-analysis
Farrall, A. J., & Wardlaw, J. M. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.07.015 · Cited by 882 · cited 1×
“BBB leakage is a feature of aging brain but also occurs early in AD [33,34].”
Molecular pathways to neurodegeneration
Bossy-Wetzel, E., Schwarzenbacher, R., & Lipton, S. A. (2004) · Nature Medicine · doi:10.1038/nm1067 · Cited by 740
Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches
Tsai, J., Grutzendler, J., Duff, K., & Gan, W.-B. (2004) · Nature Neuroscience · doi:10.1038/nn1335 · Cited by 561
Astrocyte phenotype in relation to Alzheimer‐type pathology in the ageing brain
Simpson, J. E., Ince, P. G., Lace, G., Forster, G., Shaw, P. J., Matthews, F., Savva, G., Brayne, C., & Wharton, S. B. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.015 · Cited by 381
Ihara, M., Tomimoto, H., Kinoshita, M., Oh, J., Noda, M., Wakita, H., Akiguchi, I., & Shibasaki, H. (2001) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200107000-00008 · Cited by 115
Overmyer, M., Helisalmi, S., Soininen, H., Laakso, M., Riekkinen Sr., P., & Alafuzoff, I. (1999) · Acta Neuropathologica · doi:10.1007/s004010051002 · Cited by 91 · cited 1×
“It is worth noting that the presence of small titers of the autoantibodies in healthy control subjects, matched for age, can be explained by the mild microglial activation described in normal aging [37].”
BackgroundC. Schmued, L., Raymick, J., G. Paule, M., Dumas, M., & Sarkar, S. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310010005 · Cited by 35
Cited by
Zhan, X., Stamova, B., & Sharp, F. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00042 · Cited by 351
The role of myelin damage in Alzheimer’s disease pathology
Papuć, E., & Rejdak, K. (2020) · Archives of Medical Science · doi:10.5114/aoms.2018.76863 · Cited by 188
“The above data are also in accordance with the results of biochemical studies which show that there are increased levels of antibodies against different glial-derived antigens (anti-MOG, antiMAG, anti-MBP, anti-PLP) in sera of AD patients in comparison to healthy control subjects [54].”
BackgroundResultSelf-citationMyelin in Alzheimer’s disease: culprit or bystander?
Maitre, M., Jeltsch-David, H., Okechukwu, N. G., Klein, C., Patte-Mensah, C., & Mensah-Nyagan, A.-G. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01554-5 · Cited by 66
Quantitative proteomics of synaptosome S‐nitrosylation in Alzheimer’s disease
Wijasa, T. S., Sylvester, M., Brocke‐Ahmadinejad, N., Schwartz, S., Santarelli, F., Gieselmann, V., Klockgether, T., Brosseron, F., & Heneka, M. T. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.14870 · Cited by 41
Lower Serum Antibodies Against Tau Protein and Heavy Neurofilament in Alzheimer’s Disease
Bartos, A., Fialová, L., & Švarcová, J. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180039 · Cited by 25
Metadata
- Authors
- Papuć, E., Kurys-Denis, E., Krupski, W., Tatara, M., & Rejdak, K.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2015-08-28
- Volume
- 48
- Issue
- 1
- Pages
- 115-121
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2263464408
- Cited by
- 33
- References
- 7
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Can Antibodies Against Glial Derived Antigens be Early Biomarkers of Hippocampal Demyelination and Memory Loss in Alzheimer’s Disease? https://app.cochat.ai/papers/10.3233/jad-150309
- The paper
- Papuć, E., Kurys-Denis, E., Krupski, W., Tatara, M., & Rejdak, K. (2015). Can Antibodies Against Glial Derived Antigens be Early Biomarkers of Hippocampal Demyelination and Memory Loss in Alzheimer’s Disease? Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-150309
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.